(4) Policy Briefing: A New Agenda For CMS, The Biden White House, And A Democratic Congress The Certara Market Access Channel podcast

コンテンツは Certara Evidence & Access and Certara Evidence によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャストコンテンツは、Certara Evidence & Access and Certara Evidence またはそのポッドキャストプラットフォームパートナーによって直接アップロードされ、提供されます。誰かがあなたの著作物をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal。

The Certara Market Access Channel »
(4) Policy Briefing: A new agenda for CMS, the Biden White House, and a Democratic Congress

3+ y ago 20:34

MP3•エピソードのホーム

We're finally back with a new season for the Radar Podcast, pharma's flagship intelligence briefing on all things market access, real-world evidence, and payer strategy. This program is brought to you by the experts in Certara's global Evidence & Access practice.

In this episode, we're discussing the Biden administration's policy positions, the fate of Trump-era CMS proposals, and what the new majority in the 117th Congress will mean for the biopharma industry.

Your host for this week is Max Goldstein, Director of Business Development, speaking to Ulrich Neumann, Senior Director, Access and Commercial Strategy. For any questions on the topics discussed today, please contact ulrich.neumann@certara.com or download our latest whitepapers here: https://www.certara.com/evidence-access/us-managed-markets/key-trends-us-specialty/

--- Send in a voice message: https://podcasters.spotify.com/pod/show/market-access/message

4 つのエピソード

#Science #Certara Evidence & Access #Certara Evidence